

## Special Issue

# Personalized Medicine in Otolaryngology: Novel Prognostic Markers

### Message from the Guest Editors

In recent years, the field of otolaryngology has seen massive improvements in terms of novel treatment options, ranging from checkpoint inhibitors for recurrent and/or metastatic head and neck squamous cell carcinoma, biological treatment for patients with nasal polyposis, to novel active bone-conduction hearing implants for patients with sensorineural, conductive, and mixed hearing loss. In order to further facilitate patient-selection and improve outcomes for patients, efforts have to be undertaken to identify easily obtainable prognostic markers. This Special Issue aims to collate papers that underscore recent findings and perspectives on future developments in terms of personalized treatments for patients with otolaryngological disorders.

---

### Guest Editors

Dr. Faris F. Brkic

Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria

Prof. Dr. Wolf-Dieter Baumgartner

Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria

---

### Deadline for manuscript submissions

20 October 2025



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/186223](https://mdpi.com/si/186223)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).